Department of Clinical Epidemiology and Biostatistics, McMaster University, 1200 Main Street, West Hamilton, Ontario L8N 3Z5, Canada.
J Clin Epidemiol. 2011 Dec;64(12):1311-6. doi: 10.1016/j.jclinepi.2011.06.004. Epub 2011 Jul 30.
The most common reason for rating up the quality of evidence is a large effect. GRADE suggests considering rating up quality of evidence one level when methodologically rigorous observational studies show at least a two-fold reduction or increase in risk, and rating up two levels for at least a five-fold reduction or increase in risk. Systematic review authors and guideline developers may also consider rating up quality of evidence when a dose-response gradient is present, and when all plausible confounders or biases would decrease an apparent treatment effect, or would create a spurious effect when results suggest no effect. Other considerations include the rapidity of the response, the underlying trajectory of the condition, and indirect evidence.
将证据质量评级提高的最常见原因是效果较大。GRADE 建议,如果严谨的观察性研究显示风险至少降低或增加两倍,则将证据质量评级提高一级;如果风险至少降低或增加五倍,则将证据质量评级提高两级。系统评价作者和指南制定者也可能会在存在剂量-反应梯度,并且所有可能的混杂因素或偏倚都会降低明显的治疗效果,或者当结果表明无效果时会产生虚假效果时,将证据质量评级提高。其他考虑因素包括反应的速度、病情的潜在轨迹和间接证据。